Cold Genesys, Inc. logo

Cold Genesys, Inc.

Cold Genesys, Inc., a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer Cold Genesys is a clinical-stage company focusing on the development of oncolytic viruses and immunotherapies against cancer.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.coldgenesys.com
Founded2010
Disease Focus
Development Stage
STOCK CODENon Listed
Address
6 Hutton Centre Drive, Suite #1220 CA 092707
Santa Ana
United States
Email
Contact Number
+1 714 884 3953

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cold-genesys” connections=”true” suffix=””]

Oncolytic virus technology utilizes adenoviruses, engineered to selectively replicate in targeted cancer cells resulting in targeted
cancer cell death. They are also programmed to express a human GM-CSF gene, which stimulates natural immune cells to promote a tumor-specific T cell response against tumors after oncolysis.

In 2010, Cold Genesys, acquired proprietary Oncolytic virus technology and the worldwide rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). In exchange for this, BioSante received a 19.9% ownership position in Cold Genesys.

In Aug 2015, Cold Genesys raised $10 Mn in a Series B co-led by Ally Bridge Group and WI Harper Group with participation from Whitesun Healthcare Ventures and Song Hong Fang.

In July 2014, Cold Genesys raised $13.57 Mn in a Series A Round of financing to accelerate Its ongoing Phase II/III Clinical Trial for Bladder Cancer. It was financially backed by Ally Bridge Group.